Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Bictegravir (BIC; GS-9883), a novel, potent, once-daily, unboosted inhibitor of HIV-1 integrase (IN), specifically targets IN strand transfer activity (50% inhibitory concentration [IC 50] of 7.5 ± 0.3 nM) and HIV-1 integration in cells. BIC exhibits potent and selective in vitro antiretroviral activity in both T-cell lines and primary human T lymphocytes, with 50% effective concentrations ranging from 1.5 to 2.4 nM and selectivity indices up to 8,700 relative to cytotoxicity. BIC exhibits synergistic in vitro antiviral effects in pairwise combinations with tenofovir alafenamide, emtricitabine, or darunavir and maintains potent antiviral activity against HIV-1 variants resistant to other classes of antiretrovirals. BIC displayed an in vitro resistance profile that was markedly improved compared to the integrase strand transfer inhibitors (INSTIs) raltegravir (RAL) and elvitegravir (EVG), and comparable to that of dolutegravir (DTG), against nine INSTI-resistant site-directed HIV-1 mutants. BIC displayed statistically improved antiviral activity relative to EVG, RAL, and DTG against a panel of 47 patient-derived HIV-1 isolates with high-level INSTI resistance; 13 of 47 tested isolates exhibited >2-fold lower resistance to BIC than DTG. In dose-escalation experiments conducted in vitro, BIC and DTG exhibited higher barriers to resistance than EVG, selecting for HIV-1 variants with reduced phenotypic susceptibility at days 71, 87, and 20, respectively. A recombinant virus with the BIC-selected M50I/R263K dual mutations in IN exhibited only 2.8-fold reduced susceptibility to BIC compared to wild-type virus. All BIC-selected variants exhibited low to intermediate levels of cross-resistance to RAL, DTG, and EVG (<8-fold) but remained susceptible to other classes of antiretrovirals. A high barrier to in vitro resistance emergence for both BIC and DTG was also observed in viral breakthrough studies in the presence of constant clinically relevant drug concentrations. The overall virologic profile of BIC supports its ongoing clinical investigation in combination with other antiretroviral agents for both treatment-naive and -experienced HIV-infected patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the last 14 years, four more INSTIs were approved for treatment of HIV infection: elvitegravir, dolutegravir, bictegravir and cabotegravir147–150.”
From Structure and function of retroviral integrase (2022) · cites this paper as [149]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
Walmsley, S. L., Antela, A., Clumeck, N., Duiculescu, D., Eberhard, A., Gutiérrez, F., Hocqueloux, L., Maggiolo, F., Sandkovsky, U., Granier, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215541 · Cited by 876
Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Gatell, J. M., Rockstroh, J. K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708975 · Cited by 691
A quantitative assay for HIV DNA integration in vivo
Butler, S. L., Hansen, M. S. T., & Bushman, F. D. (2001) · Nature Medicine · doi:10.1038/87979 · Cited by 687
A three-dimensional model to analyze drug-drug interactions
Prichard, M. N., & Shipman, C. (1990) · Antiviral Research · doi:10.1016/0166-3542(90)90001-n · Cited by 544
Cahn, P., Pozniak, A. L., Mingrone, H., Shuldyakov, A., Brites, C., Andrade-Villanueva, J. F., Richmond, G., Buendia, C. B., Fourie, J., Ramgopal, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61221-0 · Cited by 516
Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
Cooper, D. A., Steigbigel, R. T., Gatell, J. M., Rockstroh, J. K., Katlama, C., Yeni, P., Lazzarin, A., Clotet, B., Kumar, P. N., Eron, J. E., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708978 · Cited by 509
Clotet, B., Feinberg, J., van Lunzen, J., Khuong-Josses, M.-A., Antinori, A., Dumitru, I., Pokrovskiy, V., Fehr, J., Ortiz, R., Saag, M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60084-2 · Cited by 507
In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
Kobayashi, M., Yoshinaga, T., Seki, T., Wakasa-Morimoto, C., Brown, K. W., Ferris, R., Foster, S. A., Hazen, R. J., Miki, S., Suyama-Kagitani, A., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01209-10 · Cited by 382
Raffi, F., Jaeger, H., Quiros-Roldan, E., Albrecht, H., Belonosova, E., Gatell, J. M., Baril, J.-G., Domingo, P., Brennan, C., Almond, S., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70257-3 · Cited by 379
Shimura, K., Kodama, E., Sakagami, Y., Matsuzaki, Y., Watanabe, W., Yamataka, K., Watanabe, Y., Ohata, Y., Doi, S., Sato, M., et al. (2008) · Journal of Virology · doi:10.1128/jvi.01534-07 · Cited by 343
Research works printed but not linked: 7
- Lepik KJ, Yip B, Robbins M, Woods C, Lima VD, McGovern RA, Zhang WW, Barrios R, Montaner JSG, Harrigan PR. 2016. Prevalence and incidence of integrase drug resistance in BC, Canada 2009-2015. Abstr 23rd Conf Retroviruses Opportunistic Infect, abstr 492LB.
- ViiV Healthcare. 2015. Tivicay 50 mg film-coated tablets. ViiV Healthcare, Middlesex, United Kingdom.
- Lazerwith SE, Cai R, Chen X, Desai MC, Eng S, Jacques R, Ji M, Martin H, McMahon C, Mish M, Morganelli P, Mwangi J, Pyun HJ, Schmitz U, Stepan G, Szwarcberg J, Tang J, Tsiang M, Wang J, White K, Wiser L, Zack J, Jin H. 2016. Discovery of bictegravir (GS-9883), a novel, unboosted, once-daily HIV-1 integrase strand transfer inhibitor (INSTI) with improved pharmacokinetics and in vitro resistance profile. ASM Microbe 2016, poster 414.
- Pozniak A, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Hagins D, Buendia CB, Dorey D, Griffith S, Min S. Dolutegravir (DTG) versus raltegravir (RAL) in ART-experienced, integrase-naive subjects: 24 week interim results from SAILING (ING111762). Abstr 20th Conf Retroviruses Opportunistic Infect, abstr 179LB.
- Jones G, Ledford RM, Yu F, Chen X, Miller MD, Tsiang M, McColl DJ. In vitro resistance profile of HIV-1 mutants selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). Abstr 14th Conf Retroviruses Opportunistic Infect, abstr 627.
- Abram M, Margot N, Barnes T, Ram R, Chen X, White K, Miller M, Callebaut C. 2014. Clinical impact and characterization of HIV integrase inhibitor resistance associated with T97A: a low-level polymorphic integrase mutation, abstr POH-017. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
- 10.1310/hct1504-218 · DOI
Cited by
Clinical targeting of HIV capsid protein with a long-acting small molecule
Link, J. O., Rhee, M. S., Tse, W. C., Zheng, J., Somoza, J. R., Rowe, W., Begley, R., Chiu, A., Mulato, A., Hansen, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2443-1 · Cited by 425
Self-citation2015 update of the drug resistance mutations in HIV-1
Wensing, A. M. J., Cálvez, V., Ceccherini‐Silberstein, F., Charpentier, C., Günthard, H. F., Jacobsen, D. M., Paredes, R., Shafer, R. W., & Richman, D. D. (2015) · PubMed · doi:10.5167/uzh-122257 · Cited by 415
Sax, P. E., Pozniak, A., Montes, M. L., Koenig, E., DeJesus, E., Stellbrink, H.-J., Antinori, A., Workowski, K., Slim, J., Reynes, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32340-1 · Cited by 396
Self-citationGallant, J., Lazzarin, A., Mills, A., Orkin, C., Podzamczer, D., Tebas, P., Girard, P.-M., Brar, I., Daar, E. S., Wohl, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32299-7 · Cited by 393
Self-citationNext generation organofluorine containing blockbuster drugs
Han, J., Remete, A. M., Dobson, L. S., Kiss, L., Izawa, K., Moriwaki, H., Soloshonok, V. A., & O’Hagan, D. (2020) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2020.109639 · Cited by 313
A Survey of the Structures of US FDA Approved Combination Drugs
Das, P., Delost, M. D., Qureshi, M. H., Smith, D. T., & Njardarson, J. T. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01610 · Cited by 312
Ghosn, J., Taiwo, B., Seedat, S., Autran, B., & Katlama, C. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31311-4 · Cited by 306
Targeting Metalloenzymes for Therapeutic Intervention
Chen, A. Y., Adamek, R. N., Dick, B. L., Credille, C. V., Morrison, C. N., & Cohen, S. M. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00201 · Cited by 270
Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs
Tompa, D. R., Immanuel, A., Srikanth, S., & Kadhirvel, S. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.01.076 · Cited by 257
2017 Update of the Drug Resistance Mutations in HIV-1.
Wensing, A. M. J., Cálvez, V., Günthard, H. F., Johnson, V. A., Paredes, R., Pillay, D., Shafer, R. W., & Richman, D. D. (2016) · Europe PMC (PubMed Central) · Cited by 257
2019 update of the drug resistance mutations in HIV-1.
Wensing, A. M. J., Cálvez, V., Ceccherini‐Silberstein, F., Charpentier, C., Günthard, H. F., Paredes, R., Shafer, R. W., & Richman, D. D. (2019) · PubMed Central · Cited by 230
Molina, J.-M., Ward, D., Brar, I., Mills, A., Stellbrink, H.-J., López-Cortés, L., Ruane, P., Podzamczer, D., Brinson, C., Custodio, J., et al. (2018) · The Lancet HIV · doi:10.1016/s2352-3018(18)30092-4 · Cited by 204
Diesel, J., Finogenova, A. M., & Cramer, N. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b01181 · Cited by 185
Daar, E. S., DeJesus, E., Ruane, P., Crofoot, G., Oguchi, G., Creticos, C., Rockstroh, J. K., Molina, J.-M., Koenig, E., Liu, Y.-P., et al. (2018) · The Lancet HIV · doi:10.1016/s2352-3018(18)30091-2 · Cited by 178
HIV drug resistance against strand transfer integrase inhibitors
Anstett, K., Brenner, B., Mesplede, T., & Wainberg, M. A. (2017) · Retrovirology · doi:10.1186/s12977-017-0360-7 · Cited by 176
A systematic review of the genetic mechanisms of dolutegravir resistance
Rhee, S., Grant, P., Tzou, P. L., Barrow, G., Harrigan, P. R., Ioannidis, J. P. A., & Shafer, R. W. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz256 · Cited by 170
HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety
Scarsi, K. K., Havens, J. P., Podany, A. T., Avedissian, S. N., & Fletcher, C. V. (2020) · Drugs · doi:10.1007/s40265-020-01379-9 · Cited by 169
Zhao, A., Crutchley, R. D., Guduru, R. C., Ton, K., Lam, T., & Min, A. (2022) · Retrovirology · doi:10.1186/s12977-022-00608-1 · Cited by 156
Yant, S. R., Mulato, A., Hansen, D., Tse, W. C., Niedziela-Majka, A., Zhang, J. R., Stepan, G. J., Jin, D., Wong, M. H., Perreira, J. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0560-x · Cited by 154
Self-citationSahoo, B. M., Ravi Kumar, B. V. V., Sruti, J., Mahapatra, M. K., Banik, B. K., & Borah, P. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.628144 · Cited by 137
Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput ScreeningPreprint
Li, Y., Zhang, J., Wang, N., Li, H., Shi, Y., Guo, G., Liu, K., Zeng, H., & Zou, Q. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.01.28.922922 · Cited by 135
Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection
Deeks, E. D. (2018) · Drugs · doi:10.1007/s40265-018-1010-7 · Cited by 132
Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs
Smith, S. J., Zhao, X. Z., Passos, D. O., Lyumkis, D., Burke, T. R., & Hughes, S. H. (2021) · Viruses · doi:10.3390/v13020205 · Cited by 131
Sax, P. E., Rockstroh, J. K., Luetkemeyer, A. F., Yazdanpanah, Y., Ward, D. J., Trottier, B., Rieger, A., Liu, H., Acosta, R. K., Collins, S. E., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa988 · Cited by 129
Structure and function of retroviral integrase
Maertens, G. N., Engelman, A. N., & Cherepanov, P. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00586-9 · Cited by 124
the Montreal Primary HIV (PHI) Cohort Study Group, Oliveira, M., Ibanescu, R.-I., Anstett, K., Mésplède, T., Routy, J.-P., Robbins, M. A., & Brenner, B. G. (2018) · Retrovirology · doi:10.1186/s12977-018-0440-3 · Cited by 118
Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants
Smith, S. J., Zhao, X. Z., Burke, T. R., & Hughes, S. H. (2018) · Retrovirology · doi:10.1186/s12977-018-0420-7 · Cited by 114
Gallant, J. E., Thompson, M., DeJesus, E., Voskuhl, G. W., Wei, X., Zhang, H., White, K., Cheng, A., Quirk, E. K., & Martin, H. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001306 · Cited by 113
Self-citationMbhele, N., Chimukangara, B., & Gordon, M. L. (2021) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2021.106343 · Cited by 109
Gottlieb, G. S., Raugi, D. N., & Smith, R. A. (2018) · The Lancet HIV · doi:10.1016/s2352-3018(18)30094-8 · Cited by 108
Management of Virologic Failure and HIV Drug Resistance
McCluskey, S. M., Siedner, M. J., & Marconi, V. C. (2019) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2019.05.004 · Cited by 108
Sax, P. E., DeJesus, E., Crofoot, G. E., Ward, D. J., Benson, P. M., Dretler, R. H., Mills, A., Brinson, C. C., Péloquin, J., Wei, X., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30016-4 · Cited by 104
Self-citationWu, Y., & Meanwell, N. A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00790 · Cited by 83
Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition
Engelman, A. N. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.006901 · Cited by 78
Structural Biology of HIV Integrase Strand Transfer Inhibitors
Jozwik, I. K., Passos, D. O., & Lyumkis, D. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.06.003 · Cited by 78
Sever, B., Otsuka, M., Fujita, M., & Ciftci, H. I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073659 · Cited by 77
Synthetic Approaches to New Drugs Approved During 2016
Flick, A. C., Ding, H. X., Leverett, C. A., Fink, S. J., & O’Donnell, C. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00260 · Cited by 72
Cruciani, M., & Parisi, S. G. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222229 · Cited by 68
Andreatta, K. N., Willkom, M., Martin, R., Chang, S., Wei, L., Liu, H., Liu, Y.-P., Graham, H., Quirk, E. K., Martin, H., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz347 · Cited by 68
Self-citationSynthetic Approaches to New Drugs Approved during 2018
Flick, A. C., Leverett, C. A., Ding, H. X., McInturff, E. L., Fink, S. J., Helal, C. J., DeForest, J. C., Morse, P., Mahapatra, S., & O’Donnell, C. J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00345 · Cited by 67
Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?
Brooks, K. M., Sherman, E. M., Egelund, E. F., Brotherton, A. L., Durham, S. H., Badowski, M. E., & Cluck, D. B. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2246 · Cited by 66
Wohl, D. A., Clarke, A. E., Maggiolo, F., Garner, W., Laouri, M., Martin, H., & Quirk, E. K. (2018) · Patient · doi:10.1007/s40271-018-0322-8 · Cited by 65
Bictegravir: First Global Approval
Markham, A. (2018) · Drugs · doi:10.1007/s40265-018-0896-4 · Cited by 65
Recent Advances in the Development of Integrase Inhibitors for HIV Treatment
Trivedi, J. S., Mahajan, D., Jaffe, R. J., Acharya, A., Mitra, D., & Byrareddy, S. N. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-019-00480-3 · Cited by 60
Kityo, C. M., Hagins, D. P., Koenig, E., Avihingsanon, A., Chetchotisakd, P., Supparatpinyo, K., Gankina, N. U., Pokrovsky, V. V., Voronin, E., Stephens, J. L., et al. (2019) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002137 · Cited by 60
Acosta, R. K., Willkom, M., Martin, R., Chang, S., Wei, X., Garner, W., Lutz, J. D., Majeed, S. R., SenGupta, D., Martin, H., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02533-18 · Cited by 58
Self-citationTao, K., Rhee, S., Chu, C., Avalos, A., Ahluwalia, A. K., Gupta, R. K., Jordan, M. R., & Shafer, R. W. (2023) · Viruses · doi:10.3390/v15091932 · Cited by 55
Niu, Z.-X., Hu, J., Sun, J., & Wang, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116446 · Cited by 53
Anti-retroviral drugs: current state and development in the next decade
Zhang, X. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.01.012 · Cited by 52
Recent Advances in the Discovery of Small-Molecule Inhibitors of HIV-1 Integrase
Choi, E., Mallareddy, J. R., Lu, D., & Kolluru, S. (2018) · Future Science OA · doi:10.4155/fsoa-2018-0060 · Cited by 51
Going beyond Integration: The Emerging Role of HIV-1 Integrase in Virion Morphogenesis
Elliott, J. L., & Kutluay, S. B. (2020) · Viruses · doi:10.3390/v12091005 · Cited by 51
Maggiolo, F., Rizzardini, G., Molina, J., Pulido, F., Wit, S. D., Vandekerckhove, L., Berenguer, J., D’Antoni, M. L., Blair, C. J., Chuck, S. K., et al. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-021-00419-5 · Cited by 51
HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors
Koneru, P. C., Francis, A. C., Deng, N., Rebensburg, S. V., Hoyte, A. C., Lindenberger, J., Adu-Ampratwum, D., Larue, R. C., Wempe, M. F., Engelman, A. N., et al. (2019) · eLife · doi:10.7554/elife.46344 · Cited by 49
Rekha, T. N., & Shin, D. (2023) · Pharmaceuticals · doi:10.3390/ph16030339 · Cited by 49
Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections
Clercq, E. D. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.11.023 · Cited by 49
Mandal, S., Prathipati, P. K., Belshan, M., & Destache, C. J. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2019.04.007 · Cited by 45
Zhang, W. W., Cheung, P. K., Oliveira, N., Robbins, M. A., Harrigan, P. R., & Shahid, A. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy428 · Cited by 44
Domingo, P., Quesada‐López, T., Villarroya, J., Cairó, M., Gutiérrez, M. D. M., Mateo, G. M., Mur, I., Corbacho, N., Domingo, J. C., Villarroya, F., et al. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120948 · Cited by 44
Bonnard, D., Le Rouzic, E., Eiler, S., Amadori, C., Orlov, I., Bruneau, J.-M., Brias, J., Barbion, J., Chevreuil, F., Spehner, D., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.816793 · Cited by 42
Hassounah, S. A., Alikhani, A., Oliveira, M., Bharaj, S., Ibanescu, R.-I., Osman, N., Xu, H.-T., Brenner, B. G., Mesplède, T., & Wainberg, M. A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01695-17 · Cited by 40
Spagnuolo, V., Castagna, A., & Lazzarin, A. (2018) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000468 · Cited by 40
Peese, K. M., Allard, C. W., Connolly, T., Johnson, B. L., Li, C., Patel, M., Sorensen, M. E., Walker, M. A., Meanwell, N. A., McAuliffe, B., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01473 · Cited by 39
Sugiyama, S., Akiyama, T., Taoda, Y., Iwaki, T., Matsuoka, E., Akihisa, E., Seki, T., Yoshinaga, T., & Kawasuji, T. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127742 · Cited by 39
Barski, M. S., Minnell, J. J., & Maertens, G. N. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01877 · Cited by 37
Moranguinho, I., Taveira, N., & Bártolo, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065905 · Cited by 37
Yang, L., Li, Q., Zhou, L.-B., & Chen, S. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.08.008 · Cited by 37
Zhang, D., Yan, H.-L., Xu, X., Xu, L., Yin, Z., Chang, S., & Luo, H. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1743282 · Cited by 37
Acosta, R. K., Willkom, M., Andreatta, K. N., Liu, H., Martin, R., Parvangada, A., Martin, H., Collins, S. E., & White, K. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002454 · Cited by 37
Self-citationInvestigational Antiretroviral Drugs: What is Coming Down the Pipeline.
Gulick, R. M. (2018) · Europe PMC (PubMed Central) · Cited by 37
Pharmacokinetic drug interactions of integrase strand transfer inhibitors
Lu, C., Bednarczyk, E. M., Catanzaro, L. M., Shon, A. S. Y., Xu, J.-C., & Ma, Q. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100044 · Cited by 37
Neogi, U., Singh, K., Aralaguppe, S. G., Rogers, L. C., Njenda, D. T., Sarafianos, S. G., Hejdeman, B., & Sönnerborg, A. B. (2017) · AIDS · doi:10.1097/qad.0000000000001726 · Cited by 36
Manalel, J. A., Kaufman, J. E., Wu, Y., Fusaris, E., Correa, A. M., Ernst, J. A., & Brennan‐Ing, M. (2024) · AIDS Research and Therapy · doi:10.1186/s12981-024-00657-w · Cited by 36
Telele, N. F., Kalu, A. W., Gebre-Selassie, S., Fekade, D., Abdurahman, S., Marrone, G., Neogi, U., Tegbaru, B., & Sönnerborg, A. B. (2018) · Scientific Reports · doi:10.1038/s41598-018-25888-6 · Cited by 36
Margot, N., Ram, R. R., White, K., Abram, M. E., & Callebaut, C. (2019) · Journal of Medical Virology · doi:10.1002/jmv.25564 · Cited by 35
Self-citationBrado, D., Obasa, A. E., Ikomey, G. M., Cloete, R. E. A., Singh, K., Engelbrecht, S., Neogi, U., & Jacobs, G. B. (2018) · Scientific Reports · doi:10.1038/s41598-018-22914-5 · Cited by 34
Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes
White, K. L., Osman, N., Cuadra-Foy, E., Brenner, B. G., Shivakumar, D., Campigotto, F., Tsiang, M., Morganelli, P. A., Novikov, N., Lazerwith, S. E., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02406-20 · Cited by 33
Self-citationStructural Implications of Genotypic Variations in HIV-1 Integrase From Diverse Subtypes
Rogers, L. C., Obasa, A. E., Jacobs, G. B., Sarafianos, S. G., Sönnerborg, A. B., Neogi, U., & Singh, K. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01754 · Cited by 33
Drug Discovery and Development
Blass, B. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-411508-8.00001-3 · Cited by 33
Solórzano, R., Tort, O., García‐Pardo, J., Escribà, T., Lorenzo, J., Arnedo, M., Ruiz‐Molina, D., Alibés, R., Busquè, F., & Novio, F. (2019) · Biomaterials Science · doi:10.1039/c8bm01221k · Cited by 33
Lozano, A. B., Chueca, N., de Salazar, A., Fernández-Fuertes, E., Collado, A., Fernández, J. M., Álvarez, M., & García, F. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104717 · Cited by 33
Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
Himmel, D. M., & Arnold, E. (2020) · Pharmaceuticals · doi:10.3390/ph13060122 · Cited by 32
HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants
Smith, S. J., Zhao, X. Z., Passos, D. O., Lyumkis, D., Burke, T. R., & Hughes, S. H. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00611-20 · Cited by 32
Diastereoselective synthesis of CF 3 -oxazinoquinolines in water
Muzalevskiy, V. M., Belyaeva, K. V., Trofimov, B. A., & Nenajdenko, V. G. (2019) · Green Chemistry · doi:10.1039/c9gc03044a · Cited by 31
Koullias, Y., Sax, P. E., Fields, N. F., Walensky, R. P., & Hyle, E. P. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix542 · Cited by 30
Stellbrink, H., Lazzarin, A., Woolley, I. J., & Llibre, J. M. (2020) · HIV Medicine · doi:10.1111/hiv.12833 · Cited by 30
Fluorine in anti-HIV drugs approved by FDA from 1981 to 2023
Han, S., & Lu, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115586 · Cited by 30
Mayer, K. H., Jones, D. B., Oldenburg, C. E., Jain, S., Gelman, M., Zaslow, S., Grasso, C., & Mimiaga, M. J. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001440 · Cited by 30
Hingrat, Q. L., Collin, G., Lê, M., Peytavin, G., Visseaux, B., Bertine, M., Tubiana, R., Karmochkine, M., Valin, N., Collin, F., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy940 · Cited by 30
George, J. M., Kuriakose, S., Dee, N., Stoll, P., Lalani, T., Dewar, R. L., Khan, M. A., Rehman, M. T., Grossman, Z., Maldarelli, F. M., et al. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy221 · Cited by 29
Advances in the development of HIV integrase strand transfer inhibitors
Wang, Y., Gu, S., He, Q., & Fan, R. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113787 · Cited by 29
Chen, I., Sun, H., & Hung, C. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-021-00449-z · Cited by 29
Prathipati, P. K., Mandal, S., & Destache, C. J. (2018) · Biomedical Chromatography · doi:10.1002/bmc.4379 · Cited by 28
Long-Acting Cabotegravir for HIV/AIDS Prophylaxis
Engelman, K. D., & Engelman, A. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00157 · Cited by 27
Chang, H., Chou, P.-Y., Chou, C., & Tsai, H. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s331647 · Cited by 27
Chamberlain, N., Mena, L. A., & Brock, J. B. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab297 · Cited by 27
Tanuja, A., Ganapaty, S., & VARANASI, S. N. M. (2021) · Turkish Journal of Pharmaceutical Sciences · doi:10.4274/tjps.galenos.2020.70962 · Cited by 27
Smith, R. A., Raugi, D. N., Wu, V. H., Zavala, C. G., Song, J. K., Diallo, K. M., Seydi, M., Gottlieb, G. S., Sall, F., Diallo, M. B., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00014-19 · Cited by 26
Rigo-Bonnin, R. F., Tiraboschi, J. M., Álvarez-Álvarez, M., Pérez-Fernández, G. A., Sanjuás-Iglesias, M., Scévola, S. C., Niubó, J., Videla, S., & Podzamczer, D. (2020) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2020.113250 · Cited by 26
Imaz, A., Tiraboschi, J. M., Niubó, J., Martínez‐Picado, J., Cottrell, M. L., Domingo, P., Chivite, I., Negredo, E., Schauer, A. P., Horne, B. V., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1416 · Cited by 25
Jesumoroti, O. J., Faridoon, F., Mnkandhla, D., Isaacs, M. L., Hoppe, H. C., & Klein, R. (2019) · MedChemComm · doi:10.1039/c8md00328a · Cited by 25
Metadata
- Authors
- Tsiang, M., Jones, G. S., Goldsmith, J., Mulato, A., Hansen, D., Kan, E., Tsai, L., Bam, R. A., Stepan, G., Stray, K. M., Niedziela-Majka, A., Yant, S. R., Yu, H., Kukolj, G., Cihlar, T., Lazerwith, S. E., White, K. L., & Jin, H.
- Affiliations
- Gilead Sciences (United States) (US)
- Gilead Sciences, Foster City, California, USA
- Corresponding author
- White, Kirsten L.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2016-12
- Volume
- 60
- Issue
- 12
- Pages
- 7086-7097
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC5118987
- OpenAlex
- W2523305619
- Cited by
- 290
- References
- 50
- Citations by year
- 2026: 19 · 2025: 26 · 2024: 24 · 2023: 25 · 2022: 24 · 2021: 40 · 2020: 37 · 2019: 38 · 2018: 36 · 2017: 18 · 2016: 2
- FWCI
- 28.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- bictegravir, antiviral activity, drug resistance, integrase inhibitors, dolutegravir, raltegravir, elvitegravir, cross-resistance, viral breakthrough, tenofovir alafenamide, emtricitabine, darunavir, drug selectivity
- MeSH terms
- Raltegravir Potassium, Dolutegravir, Amides, Cell Line, Drug Synergism, Heterocyclic Compounds, 3-Ring, Heterocyclic Compounds, 4 or More Rings, Humans, Mutation, Oxazines, Piperazines, Pyridones, HIV-1, Anti-HIV Agents, HIV Integrase, HIV Integrase Inhibitors, Drug Resistance, Viral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.